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ABSTRACT 
Migraine is a common disabling neurological condition that is associated with several premonitory 
symptoms that can occur days before the headache onset. The most commonly reported premonitory 
symptom is marked fatigue that has been shown to be highly predictive of an ensuing migraine attack. 
The locus coeruleus (LC) is a key nucleus involved in arousal that has also been shown to impact pain 
processing. It provides one of the major sources of noradrenaline to the dorsal horn of the spinal cord and 
neocortex. Given the clinical association between migraine, sleep-wake regulation and fatigue we sought 
to determine if LC modulation could impact migraine-related phenotypes in several validated preclinical 
models of migraine. To determine its role in migraine-related pain, we recorded dural nociceptive-evoked 
responses of neurons in the trigeminocervical complex, which receives trigeminal primary afferents from 
the durovascular complex. Additionally, we explored the susceptibility to cortical spreading depression 
initiation, the presumed underlying phenomenon of migraine aura. 
Our experiments reveal a potent role for LC disruption in the differential modulation of migraine-related 
phenotypes, inhibiting dural-evoked activation of wide dynamic neurons in the trigeminocervical complex 
whilst increasing cortical spreading depression susceptibility. This highlights the potential divergent 
impact of LC disruption in migraine physiology, which may help explain the complex interactions between 
dysfunctional arousal mechanisms and migraine. 
 
 
 
 
 
 
 
INTRODUCTION 
Migraine ranks as the 2nd most common cause of years lost to disability globally [10]. Despite extensive 
research and clinical development, there remains a major gap in migraine treatment. To date, the majority 
of studies have focused on targeting migraine pain [13; 16; 37]; however, there is an increasing 
understanding of the importance of premonitory (prodromal) symptoms as the earliest identifiable 
predictors of an ensuing attack [7; 24]. While the literature on the epidemiology of premonitory symptoms 
is not entirely resolved, key neurological symptoms such as fatigue have emerged as highly prevalent and 
highly predictive attack hallmarks [12; 22; 43]. The mechanisms underlying the presence of abnormal 
fatigue and its relationship with migraine-related nociceptive processing remain enigmatic. Migraine is 
intrinsically linked with regulation of sleep-wake cycles, with sleep disruption a commonly reported 
migraine trigger, while sleep itself is commonly reported for attack normalisation [31]. The wake 
promoting locus coeruleus (LC) shows clear diurnal activity levels [30] with increased activity during 
arousal and almost complete inactivity during sleep. As such, we sought to explore the impact of 
dysregulation of the LC on migraine-related phenotypes in validated preclinical models. 
A potential role for the LC in migraine pathophysiology is supported by both preclinical and clinical 
evidence. It is responsive to trigeminovascular activation [50; 51] and several human neuroimaging 
studies have highlighted altered activity and functional connectivity of the dorsal rostral pons (that 
contains the LC amongst other nuclei), in migraine [2; 33; 35; 44]. Functionally, the LC modulates a wide 
variety of networks having a key role in arousal, cognition, nociception and stress circuits [45] via 
descending projections to the spinal cord and ascending projections throughout the CNS. These ascending 
and descending projections have been shown to have divergent effects on behaviour, with descending 
projections largely regulating spinal nociception [27] and ascending projections involved in multiple 
processes including nociception, stress responses, aversive behaviours and cognition [27; 45]. 
Importantly, the LC may directly modulate spinal trigeminal nucleus neurons [42] and its 
stimulation results in α2-adrenoceptor dependent [25] cerebral hypoperfusion [23], which is a known 
trigger of cortical spreading depression (CSD) [49], the presumed underlying phenomenon of migraine 
aura [8]. In the present study, we characterised the impact of LC modulation in two validated animal 
models of migraine, acute dural-evoked activation of the trigeminovascular system and the threshold for 
the induction of CSD. First, we determined the impact of acute and chronic ablation of the LC on 
trigeminovascular nociceptive responses that are relevant to headache, and identified the noradrenergic 
receptor subtypes responsible for the observed changes. In addition, we explored the impact of chronic 
LC ablation on the electrical and chemical thresholds for CSD induction. Some data have been presented 
previously in preliminary form [53; 54]. 
 
MATERIALS AND METHODS 
All experiments were conducted in accordance with the UK Home Office Animals (Scientific Procedures) 
Act 1986 and consistent with the ARRIVE guidelines and the guidelines of the Committee for Research and 
Ethical Issues of International Association for the Study of Pain (Zimmermann, 1983). Male Sprague-
Dawley rats (n = 97, 220-380 g, Charles River, UK) were maintained and group-housed under standard 
conditions (12-hour light-dark cycles; lights on 07:00) with food and water available ad libitum. All animals 
were randomly assigned to experimental groups based on appropriate sample size calculations (G*Power; 
[19]) and all analyses were conducted by an observer blinded to the experimental grouping. To avoid 
confounding effects regarding the diurnal cycle, all experiments were performed between the hours of 
10:00 and 15:00.  
1. Chronic ablation of LC 
A subset of rats (n = 58, 240-300 g) were injected with either 50mg/kg DSP-4 (N-(2-Chloroethyl)-N-ethyl-
2-bromobenzylamine hydrochloride, Sigma, UK), a neurotoxin that initially selectively destroys 
noradrenergic projections and cells from the LC [40], or saline intraperitoneally 15 days before surgery. 
Due to the instability and light sensitivity of DSP-4, dilutions in saline were prepared immediately before 
injection. DSP-4 was observed to induce a characteristic general decrease in locomotor activity within the 
first 2 hours after injection and animals were more lethargic throughout the first 4 days and had a 16% 
mortality rate within the same period [48]. 
2. In vivo preparation 
2.1 Common surgery 
On the day of the surgery, rats were initially anesthetised with isoflurane (IsoFlo, 5%, Abbott, UK) and 
maintained with intravenous propofol infusion (Propoflo, 33-50 mg/kg/h, Abbott). The left femoral artery 
and vein were cannulated for blood pressure recordings and infusion of anaesthetic, respectively. A 
tracheotomy was performed to ventilate the animal with oxygen-enriched air and monitor the end-tidal 
CO2 throughout the experiment to keep within physiological parameters (3.5-4.5%). A rectal probe 
connected to a heating pad was used to keep the body temperature constant at 36.5-37°C. Rats were 
placed in a stereotaxic frame and underwent one of the experimental surgical preparations and 
experimental procedure as detailed below. 
Following each experiment, animals were euthanized by an overdose of intravenous pentobarbitone 
(Euthathal, 200 mg/kg, Merial, UK). When the tissue was needed for immunohistochemistry, the animals 
were perfused with 300ml of 0.01M cooled heparinised phosphate buffer saline (PBS), followed by 250ml 
of 4% paraformaldehyde in 0.01M PBS (pH 7.4). The brain and spinal cord were removed and stored for 1 
hour in the same fixative and then placed in a cryoprotectant solution (30% sucrose in 0.01M PBS) for at 
least 48 h before being serially sectioned on a freezing cryostat. 
Physiological data for all experiments were displayed and saved on a personal computer using an online 
data analysis system (Power 1401plus and Spike5 v8.04 software, CED, UK). 
2.2 Dural-evoked trigeminal activation in the trigeminocervical complex 
A parietal craniotomy provided access to the dura mater overlying the middle meningeal artery (MMA) 
and the area was covered in mineral oil. To access the trigeminocervical complex (TCC), a partial 
laminectomy of the first cervical vertebra was performed and the dura mater was opened to expose the 
caudal medulla. After completion of the surgery, animals were left to stabilize for at least 30 min before 
recording.  
Stimulation of perivascular afferents of the trigeminal nerve was performed by placing a bipolar 
stimulating electrode on the dura mater adjacent to the MMA. Dural nociceptive neurons in the TCC were 
identified via electrical stimulation (8-15 V, 0.5 Hz, 0.3-0.5 ms, 20 square wave electrical pulses) of the 
dura mater. Stimulation parameters commonly activated Aδ-fibers with latencies between 5 – 20 ms 
range, and less frequently, C-fibers with latencies greater than 20 ms. 
Tungsten microelectrodes (0.5–1.5 MΩ) were used to record extracellularly from neurons in the TCC 
activated by dural electrical stimulation and with cutaneous facial receptive fields in the ophthalmic 
dermatome. The signal from the recording electrode was fed via an AC preamplifier (Neurolog NL104, 
gain x1000), through filters (NL125, bandwidth 300Hz to 20KHz) and a 50 Hz noise eliminator (Humbug), 
then to a second-stage amplifier (Neurolog NL106, variable gain x20 - x90), a gated amplitude 
discriminator (Neurolog NL201) and an analogue-to-digital converter (Power 1401plus, CED, UK) 
connected to a computer where it was processed and stored (Spike5 v8.04 software, CED, UK). 
When a cluster of neurons sensitive to stimulation of the ophthalmic dermatome of the trigeminal nerve 
was identified, it was tested for convergent input from the dura mater. Trains of 20 stimuli were delivered 
at 5 min intervals to assess the baseline response to dural electrical stimulation. Responses were analysed 
using post-stimulus histograms with a sweep length of 100 ms and a bin width of 1 ms. When stable 
baseline values of the stimulus-evoked responses were achieved (average of 3 stimulation series), 
responses were tested for up to 60 min following physiological intervention. Following the experiment, 
animals were euthanized and electrolytic lesions were performed in the TCC (150 µA, 120 s) to confirm 
the location of the recording electrode. 
2.3 Acute lesion and drug injection in the LC 
Rats were placed in a stereotactic frame with the nose tilted down so that bregma was 2.33 mm below 
lambda. A craniotomy of approximately 2 x 2 mm was performed on the interparietal bone to gain access 
to the LC. A concentric bipolar tungsten microelectrode, or a four-barrelled glass micropipette was placed 
in the LC (anterioposterior -3.4, mediolateral -1.3, dorsoventral -6.25 mm from lambda) for electrolytic 
lesion (200µA, 500µs, 30Hz during 3 min) or for microinjection, respectively. After each experiment, the 
location of the lesion or microinjection was confirmed by cryosectioning the brainstem. 
Yohimbine hydrochloride, an α2 adrenoreceptor antagonist (10 mg/ml), clonidine hydrochloride, an α2 
adrenoreceptor agonist (1 or 10 mg/ml), phenylephrine hydrochloride, an α1 adrenoreceptor agonist (10 
mg/ml) or Chicago Sky Blue 6B powder (2%) were dissolved in saline and injected at a volume of 210nl. 
Doses were chosen based on literature and preliminary studies [1; 26; 46; 55]. 
2.4 Superior sagittal sinus (SSS) stimulation 
In animals treated with saline or DSP-4, to gain access to the superior sagittal sinus (SSS), the skull was 
exposed and a craniotomy of the parietal bone was performed with saline-cooled drilling from bregma to 
lambda. Two platinum hook electrodes were then placed on the dura mater over the SSS. Effort was taken 
to minimize contact between the cortex and stimulating electrodes to reduce the risk of current spread 
to the cortex. The area was bathed in warmed mineral oil and the animals rested for 1 hour to minimize 
non-specific c-Fos protein expression. Animals were then randomly divided into two experimental groups 
as follows: 
1. Sham controls: after the 1 hour rest period with the electrodes over the SSS, animals remained in 
the frame for a further 2 hours, receiving no stimulation or any other manipulation (DSP-4: n = 6; 
saline: n = 6). 
2. Stimulation: after the 1 hour rest period with the electrodes over the SSS, animals received 2 
hours of electrical stimulation (0.5 Hz, 0.5 ms duration at 20-28V; DSP-4: n = 6; saline: n = 6). 
Following the experiment, animals were euthanized and perfused as described above. 
2.5 Cortical spreading depression (CSD) 
In animals treated with saline or DSP-4 (n = 14 / group), anterior to lambda, a craniotomy of approximately 
2 x 2 mm was performed in each parietal bone using a saline-cooled drill and dura mater was removed. 
This area was used for electrical or chemical CSD induction. Posterior to bregma, a similar area was drilled 
in each parietal bone and dura mater was also removed. In this area, a glass pipette with a tip diameter 
of 10 µm filled with 3M NaCl was placed 500 µm below the cortical surface (layer 4), for cortical steady 
state potential recording (direct current (DC) shift). The saline filled glass pipette was coupled to a 
micropipette holder containing an Ag/AgCl pellet to facilitate connection to a high-impedance headstage. 
An Ag/AgCl reference electrode was placed subcutaneously on the neck for differential recording. The 
signal was fed via a DC preamplifier (Neurolog NL102, gain x1000), through filters (NL125) and a 50 Hz 
noise eliminator (Humbug), then to a second-stage amplifier (Neurolog NL106) and an analogue-to-digital 
converter (Power 1401plus, CED, UK) connected to a computer where it was processed and stored (Spike5 
v8.04 software, CED, UK) [29]. 
Following 30 minutes of baseline recordings in the left hemisphere, the left cortex was electrically 
stimulated at 5-minute intervals with a bipolar electrode by increasing the electric charge (5, 12.5, 25, 50, 
100, 150, 200, 250, 300, 400, 500, 600, 800, 1000, 1200 µC) until a CSD was induced. After obtaining the 
electrical threshold for CSD in the left hemisphere, baseline recordings were performed for 30 minutes in 
the right hemisphere, followed by chemical induction by placing a cotton ball soaked in 1M KCl on the 
cortex surface. CSDs were counted for 1 hour with KCl refreshed every 15 minutes (5 µl). Following the 
experiment, animals were euthanized and perfused as described above. We do not expect an ordering 
effect of testing CSD susceptibility on ipsi- and contralateral hemispheres in the same animal as CSDs do 
not propagate to and have been shown to have little effect on the contralateral hemisphere [18]. To 
minimize this, we conducted the electrical-induction protocol first, as it generates a single CSD wave and 
as such is the least disruptive to cortical function. Further, to control for a potential ordering effect, the 
protocol was identical between saline and DSP-4 treated rats. 
3.  Immunohistochemistry 
Cryosectioned tissue (30 μm) spanning the TCC (trigeminal nucleus caudalis, cervical spinal cord levels C1 
and C2), the LC, and the cortex, were collected in an antifreeze solution (30% ethylene glycol, 20% glycerol 
in 0.01M PBS) and stored at -20 °C until used. 
In rats treated with DSP-4 or saline, the effectiveness of DSP-4 treatment was determined by 
immunoreaction to dopamine-β-hydroxylase (DBH) in the LC, cortex and TCC. Sections of the LC, cortex 
and TCC (n = 2 per animal) were washed, blocked and incubated with a mouse anti-DBH antibody (1:300, 
overnight at 4 °C; MAB308, Millipore, UK). Immunodetection was visualised with a fluorescent goat anti-
mouse secondary antibody (1:500, 90 min at RT; Alexa Fluor 568, A11031, Thermo Fisher, UK). Sections 
were washed in 0.01M PBS, mounted on glass slides, cover-slipped with Vectashield® (Vector 
Laboratories, UK) and analysed by fluorescent microscopy. Quantification of the expression of DBH was 
performed by a blinded researcher in ImageJ 1.49v software by measuring the percentage of the area 
stained, adjusting the same threshold for all the images, and the mean for each animal was calculated (n 
= 2 sections per animal, bilateral average). Values are expressed as the percentage loss of DBH staining. 
Saline-treated controls were considered to have 100% staining. 
In rats where the SSS was stimulated, neuronal activation of the TCC was assessed by detecting the 
immunoreactivity to c-Fos in the TCC. Sections of the TCC (n = 12 per animal) were washed, blocked and 
incubated with a rabbit anti-c-Fos antibody (1:10000, overnight at 4 °C; ABE457, Millipore). 
Immunodetection was achieved with a goat anti-rabbit biotinylated secondary antibody (1:500, 90 min at 
RT; BA-1000, Vector Laboratories), followed by an ABC solution amplification (1:200, 30 min at RT; ABC 
Elite Kit, Vector Laboratories) and a colorimetric reaction with 3,3’-diaminobenzidine (DAB) Peroxidase 
Substrate Kit (1:50, 1-5 min at RT; SK-4100, Vector Laboratories). Sections were washed in 0.01M PBS, 
mounted on glass slides, dehydrated and cover-slipped with DPX (Sigma, UK). The expression of c-Fos was 
identified by a blinded researcher via the identification of c-Fos-immunoreactive nuclei that were clearly 
distinguishable from the background level. Quantification of the expression of c-Fos in the TCC (laminae 
I, II and V) was performed by two independent counters using an optical light microscope. Values are 
expressed as the median and interquartile ranges per animal.  
4.  Statistical Analysis 
Statistical analysis of raw data was performed using IBM SPSS 22.0 software and graphs were plotted with 
SigmaPlot 12.5 software. For each study, n was chosen to obtain a statistical power of 80-90% and 
analyses of power were performed with G*Power software [19]. Regarding CSD experiments, animals 
were included in the analysis only if data from both electrical and chemical stimulation were obtained. 
For the electrical stimulation, a threshold corresponding to the lowest current needed to induce a CSD 
was determined for each animal. For chemical stimulation, the number of CSDs where the cortical steady 
state potential was altered by at least 5mV were counted over one hour. 
For CSD experiments and immunohistochemistry, we first tested for normality using the Kolmogorov-
Smirnov test. If data were normally distributed, an independent Student’s t test was used for comparison 
(data expressed as mean ± SEM). If data were not normally distributed, we used Kruskal-Wallis test with 
Monte Carlo exact test post-hoc correction (CI of 95%) and Mann Whitney U test for comparison with 
Bonferroni post-hoc correction (data expressed as a median with interquartile range). 
For TCC recordings, data collected of Aδ-fiber activation represent the normalized data for the number of 
cells firing over a 10 ms period in the region 5-20 ms post-stimulation over 20 sweeps and is expressed as 
mean ± SEM. We first analysed if there was a significant effect over time in the raw data by using an 
ANOVA for repeated measures with Bonferroni post-hoc correction for multiple comparisons; if Mauchly's 
test of sphericity was violated, appropriate corrections to the degrees of freedom were made according 
to Greenhouse-Geisser [20]. If the ANOVA for repeated measures was significant, we proceeded to 
conduct post-hoc analyses. For post-hoc analyses, we first compared the similarity of baseline responses 
across groups. If baseline responses were not different, we compared the effect of the acute LC lesion or 
the yohimbine, clonidine or phenylephrine microinjection in the LC at each time point (30 and 60 min 
post-lesion; 1, 5, 15, 30, 45 and 60 min post-injection) with the control group (electrode placed in the LC 
or saline injection). Data was plotted as percentage of the mean of the three baselines obtained either 
before lesioning or injecting in the LC (normalized data). Animals were only included in the analysis if 
lesions or microinjections were performed in the LC.  
RESULTS 
Locus Coeruleus modulation 
We applied three strategies for modulating the LC. First, to determine the impact of LC disruption we 
electrolytically lesioned the LC. Second, to model a more chronic depletion of LC noradrenergic fibres we 
utilised DSP-4, a toxin that is known to ablate selectively LC noradrenergic neurons [40] due to its uptake 
via the noradrenaline transporter. Finally, we explored the impact of acute pharmacological modulation 
of the LC to characterise potential underlying receptor mechanisms. 
1. Acute disruption of the LC inhibits dural-evoked trigeminovascular activation 
To assess the impact of disrupted LC signalling, we electrolytically lesioned the LC in anesthetised rats and 
monitored the impact of LC disruption on dural-evoked trigeminovascular activation in the 
trigeminocervical complex (TCC), using in vivo extracellular electrophysiology that is a well-established 
preclinical model of migraine-related nociceptive processing. As illustrated in Figure 1A, electrical 
stimulation of the perivascular afferents of the trigeminal nerve results in activation of 2nd order ascending 
projections from the TCC that can be recorded in vivo (Figure 1B). 
Following the establishment of stable dural-evoked wide dynamic range neuronal responses, a concentric 
bipolar electrode was lowered into the LC in agreement with the atlas of Paxinos and Watson [38]. 
Placement of the electrode alone without stimulation induced a stable non-significant decrease of TCC 
dural-evoked neuronal activation (72 ± 11%; t(5) = 1.93, p = 0.112; Figure 1C). Subsequent electrolytic 
lesioning of the LC (pulses of 200 µA, 30Hz, 500µs during 3 min) resulted in a significant reduction in dural-
evoked neuronal activation (F6,90 = 4.361, p = 0.001), reaching its maximum at 60 minutes post lesion (42 
± 11%; t(5)= 3.24, p = 0.023; Figure 1C), indicating a decrease in dural-evoked trigeminal activation. There 
were no significant differences in baseline spontaneous firing throughout the entire experiment, 
suggesting the LC effects were nociceptive specific (F11,110 = 0.693, p = 0.74). Animals were only included 
in the analysis if anatomical lesions were located in the LC. 
2. Chronic disruption of the locus coeruleus with DSP-4 
Given the anti-nociceptive effect of acute LC disruption and the previously reported anti- and pro-
nociceptive effects of LC activation [15; 27], we considered that electrolytic lesioning of the LC may initially 
result in acute activation of the LC and increased noradrenergic signalling at its terminals. Therefore, to 
confirm the anti-nociceptive effect of LC disruption on dural-evoked trigeminovascular activation, we 
sought to chronically ablate LC noradrenergic neurons. 
Two weeks following a single intraperitoneal injection of DSP-4 (50mg/kg), a well-established selective 
toxin for LC noradrenergic neurons that acts via noradrenaline transporter uptake mechanisms [40], we 
observed a significant reduction in noradrenergic neurons in the LC as identified by decreased dopamine-
β-hydroxylase (DBH) immunoreactivity, compared to saline treated rats (n = 25 / group, 54 ± 5% reduction; 
t(48) = 6.32, p ≤ 0.0001; Figure 2A-B). We also observed a significant reduction in DBH immunoreactive 
processes, most likely as a result of a loss of LC projection neurons in the cortex (n = 4 / group, 92.9 ± 3.5% 
reduction; t(6) = 14.15, p ≤ 0.0001) and upper spinal cord (n = 4 / group, 90.2 ± 4.3% reduction; t(6) = 2.58, 
p = 0.043) when comparing DSP-4 to saline treated rats. 
3. Chronic disruption of the LC inhibits dural-evoked trigeminovascular activation 
Animals randomly assigned to receive either saline or DSP-4 (n = 12 each) were further subjected to sham 
or electrical stimulation (n = 6 per group) of the SSS to induce dural-evoked nociceptive activation of the 
trigeminovascular system (Figure 2C). Neuronal activation was then analysed by immunohistochemical 
detection of the marker of neuronal activation c-Fos within the dorsal horn of the TCC (Figure 2D). 
Electrical stimulation of the SSS in saline treated animals induced a significant four-fold increase in 
neuronal activation in the TCC compared to sham treated rats (U = 0, p = 0.006, Figure 2E). However, in 
animals receiving DSP-4, where the LC was chronically disrupted, stimulation of the SSS failed to induce 
an increase in neuronal activation, showing similar levels of c-Fos expression as sham animals (U = 7, p = 
0.144, Figure 2E). Thus, both acute lesioning and chronic ablation of the LC inhibits dural-evoked 
trigeminovascular activation at the level of the TCC. 
4. α2-adrenoceptors-dependent inhibition of LC activity decreases dural-evoked trigeminovascular 
activation 
Given our demonstration of the anti-nociceptive effects of acute and chronic disruption of the LC, we next 
sought to explore the impact of its pharmacological modulation through adrenoceptors using in vivo 
electrophysiology of dural-evoked trigeminovascular activation in the TCC combined with local 
microinjection into the LC. 
In agreement with an inhibitory action on LC activity, the microinjection of the α2-adrenoceptor agonist 
clonidine in the LC significantly inhibited TCC activation in a dose-dependent manner (F4.45,66.8 = 12.96, p ≤ 
0.0001, Figure 3A), reaching a significant decrease at 30 minutes after injection of the lowest 
concentration (1mg/ml, t(12) = -2.72, p = 0.019) and at 5 minutes after injection of the highest 
concentration (10mg/ml, t(9) = -7.56, p ≤ 0.0001). An effect that was blocked when pre-treating with the 
α2-adrenoceptor antagonist yohimbine (F11,77 = 0.88, p = 0.561, Figure 3A). Yohimbine alone microinjected 
in the LC did not have an effect on dural-evoked responses in the TCC (F11,110 = 0.44, p = 0.94, Figure 3B). 
There were no significant differences in baseline spontaneous firing throughout the entire experiment, 
suggesting the LC effects were nociceptive specific (F11,220 = 0.92, p = 0.518). 
5. LC modulates dural-evoked trigeminovascular activation through α1-adrenoceptors 
Given the inhibitory actions of α2-adrenoceptor activation and disruption of the LC, we sought to explore 
the impact of modulation of LC α1-adrenoceptors that has previously been reported to be pro-nociceptive 
[39]. Microinjection of the α1-adrenoceptor agonist phenylephrine into the LC resulted in an acute 
reduction (81 ± 5%, t(10) = -2.54, p = 0.029) in dural-evoked TCC neuronal activation that transitioned to 
increased dural-evoked TCC neuronal activation (118 ± 8%, t(10) = 3.01, p = 0.013, Figure 3C) over the one 
hour recording window. This is in agreement with a prolonged facilitation of nociceptive responses 
demonstrated by others [39]. There were no significant differences in baseline spontaneous firing 
throughout the entire experiment, suggesting the LC effects were nociceptive specific (F1.49,14.89 = 1.68, p 
= 0.105). 
6. Chronic disruption of the LC increases susceptibility to cortical spreading depression 
Given the impact of LC disruption on dural-evoked trigeminovascular activation, its previously identified 
role in cortical blood flow regulation [23] and the fact that it provides the only source of neocortical 
noradrenaline [5; 32; 41], we sought to explore the effect of LC disruption on cortical spreading depression 
(CSD), the presumed underlying phenomenon of migraine aura [3; 4; 52].  
A separate randomly assigned cohort of rats were injected with either saline or DSP-4 (n = 25) and studied 
to measure their CSD susceptibility. CSD can be induced with several methods; the most robust methods 
being electrical and chemical stimulation. Electrical stimulation allows the determination of an individual 
CSD threshold, while chemical stimulation determines the number of CSDs that occur after the application 
of the stimulus. To reduce the number of animals used and in accordance with previous studies [28], we 
used the electrical method to determine the CSD threshold in the left hemisphere and subsequently the 
chemical method to determine the number of CSDs that occurred in response to repetitive KCl application 
over the right hemisphere (Figure 4D). 
Chronic disruption of the LC via DSP-4 treatment resulted in a significant decrease in the threshold 
required to induce CSD when compared to saline treated rats, from 209 ± 58 µC to 43 ± 7 µC (U = 43, p = 
0.036), indicating an increased susceptibility to CSD initiation (Figure 4A-C). In agreement with an 
increased susceptibility to CSD, application of 1M KCl over the cortex in DSP-4 treated rats resulted in a 
significant increase in the number of CSDs recorded over the one hour period from 13 ± 2 to 20 ± 2 (t(23) = 
-2.5, p = 0.018, Figure 4E-G), that was more prominent in the final 30 minutes of the recording 
(Supplementary Figure 1).  
DISCUSSION 
Our experiments reveal a potent role for LC dysregulation in the modulation of dural-evoked 
trigeminovascular activation in the TCC and the susceptibility to CSD, the presumed underlying 
mechanism of migraine aura. Using two different validated preclinical models for migraine, we have 
identified that LC disruption decreases TCC activation to durovascular nociceptive stimulation. 
Importantly, activation of the LC has demonstrated divergent effects on pain, with both anti-and pro-
nociceptive effects [15; 27]. To confirm that it was reduced LC signalling that was responsible for the 
observed anti-nociceptive effects, we chronically ablated LC noradrenergic projections and recorded TCC 
dural-evoked responses two weeks later. 
The observed decrease in trigeminovascular activation was mimicked by the α2-adrenoceptor agonist 
clonidine that has been shown to inhibit LC neuronal activity [17; 34], suggesting that acute and chronic 
reductions in LC derived noradrenergic signalling is antinociceptive at the level of the TCC. This is further 
supported by the facilitation of TCC dural-evoked trigeminal activation by the α1-adrenoceptor agonist 
phenylephrine that has previously been shown to be pro-nociceptive and excites LC neurons [36; 39]. 
Importantly, there was no significant alteration of background trigeminovascular activity suggesting that 
the observed effects were nociceptive specific. As such, we hypothesise that the LC may be a key nucleus 
involved in sleep-induced migraine attack normalisation. Locus coeruleus activity is lowest during sleep 
[30] and as such sleep-induced reductions in LC activity may act to inhibit aberrant nociceptive-specific 
trigeminal activity at the level of the TCC and reduce the sensory input to the perturbed migraine brain 
[3]. Correspondingly, it is known that TCC neuronal excitability increases in migraine patients as they near 
the next attack [47]. As such, it could be hypothesised that decreasing LC activity would act to normalise 
this developing excitability with subsequent impacts on LC arousal related mechanisms (Figure 5), leading 
to abnormal fatigue [21; 22]. As discussed, the LC has been shown to have divergent effects on spinal 
nociception, with both pro- and anti-nociceptive effects [15; 27]. This is likely due to the heterogeneous 
population of LC neuronal projections with both descending and ascending pathways [27]. As we recorded 
wide dynamic range neuronal responses in the TCC as a surrogate marker of trigeminal mediated 
nociceptive activation, we are unable to determine if LC ablation or pharmacological modulation impacts 
pain behaviours in conscious freely behaving animals. Future studies should determine the specific effects 
of targeting ascending and descending pathways individually in such conditions. 
Given that LC ablation with DSP-4 depleted cortical and spinal noradrenergic expression, we hypothesised 
that loss of ascending noradrenergic signalling to the cortex would render it hyper-excitable and decrease 
the threshold for CSD. This is in agreement with the ability of LC stimulation to alter cortical blood flow 
[23]. Chronic ablation of the LC resulted in a significant decrease in the electrical threshold required to 
induce CSD and a significant increase in the number of CSD’s induced by repetitive KCl application to the 
cortex. Our results suggest that dysregulation of the LC may increase the likelihood of CSD induction and 
migraine aura. This is in agreement with a previous study where indirect activation of the LC via vagus 
nerve stimulation [11; 14] decreased the susceptibility to CSD [9]. Importantly, there remains some 
controversy over the impact of LC ablation on cortical extracellular noradrenaline levels [40], as DSP-4 
treated animals have been shown to have unchanged or increased extracellular concentrations in the 
cortex despite decreased tissue levels [6]. This increase is thought to result from passive spread from non-
coerulean sources combined with a lack of local noradrenaline uptake. As such, local tissue decreases may 
occur in the presence of an increased extracellular concentration of noradrenaline that may augment CSD 
susceptibility. 
Taken together, our results show a direct involvement of the LC in the regulation of migraine 
pathophysiology, whereby dysfunctional LC signalling may alter attack susceptibility. Although the existing 
models cannot reproduce the intricate modulation that the LC exerts throughout the CNS, we determined 
that decreased spinal LC noradrenergic signalling inhibits dural-evoked trigeminal activation at the level 
of the TCC. This highlights a potential anti-nociceptive action of LC inhibition on migraine-related pain. 
Conversely, decreased cortical LC noradrenergic signalling reduced the threshold for CSD induction, 
suggesting the potential for LC dysregulation to impact the occurrence of migraine aura. Our results 
highlight the LC and its noradrenergic projections as a key nucleus in the regulation of migraine 
pathophysiology. Given the arousal-related functions of the LC, its role in stress regulation and cognition, 
we further predict that the dysfunctional LC signalling may in part underlie migraine-associated symptoms 
including abnormal fatigue.  
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LEGENDS 
Figure 1. Acute lesion of the LC disrupts trigeminovascular activation in a preclinical migraine model. 
(A) Schematic representation of the experimental setup of the model of dural-evoked trigeminovascular 
activation. A bipolar stimulating electrode is placed over the middle meningeal artery (MMA) to induce 
nociceptive activation of trigeminal afferents that signal via the trigeminal ganglion (TG) and innervate 
the dural vasculature, whilst projecting centrally to the trigeminocervical complex (TCC). A recording 
electrode placed in the TCC and a concentric bipolar tungsten electrode or a glass pipette placed in the 
locus coeruleus (LC) allow for recording and lesion/microinjection respectively. (B) An example TCC 
response showing neuronal activation (in grey) to dural stimulation (dashed line). (C) Time course changes 
in the average response of dural-evoked Aδ-fiber trigeminal neurons after placement of an electrode in 
the LC (control) or electrolytic lesion of the LC. Placement of an electrode in the LC (n = 6) induced a non-
significant decrease in dural-evoked nociceptive neuronal activation in the trigeminocervical complex 
(TCC) (white bars). Subsequent electrolytic lesioning of the LC (n = 6) induced a significant decrease in 
dural-evoked neuronal activation in the TCC when compared to control (30min: t(5) = 2.76, p = 0.04; at 60 
min: t(5) = 3.24, p = 0.023, grey bars) (AMP, amplitude; C1, first cervical level. Data are expressed as mean 
± SEM, *p < 0.05). 
 
Figure 2. DSP-4 treatment chronically disrupts LC noradrenergic projections and inhibits 
trigeminovascular activation. (A) Dopamine-β-hydroxylase (DBH) immunofluorescence in the locus 
coeruleus (LC) in saline and DSP-4 treated animals (white scale bar = 100 µm, white outlines were 
extracted from rat brain atlas [38]). (B) Percentage change in LC area immunoreactive for DBH in saline (n 
= 25, grey box) and DSP-4 (n = 25, black box) treated animals normalized to controls. DSP-4 treatment 
induced a significant loss of noradrenergic cells in the LC to 54 ± 5% compared to saline treated animals 
(t(48) = 6.32, p < 0.001) (Data are expressed as median and interquartile ranges ***p = 0.000027). (C) 
Schematic representation of the experimental setup of nociceptive trigeminovascular activation as a 
model of migraine-related pain processing. A bipolar stimulating electrode was placed over the superior 
sagittal sinus (SSS) to induce dural-evoked activation of trigeminal afferents from the trigeminal ganglion 
(TG) that innervate the dural vasculature. Neuronal activation was analysed by c-Fos 
immunohistochemistry detection within the trigeminocervical complex (TCC). (D) Photomicrographs 
showing c-Fos immunohistochemistry expression in the TCC in a representative animal of each 
experimental group. (E) Number of c-Fos immunoreactive positive cells in the TCC (n = 6 / group). Electrical 
stimulation induced a four-fold increase in neuronal activation in the TCC compared to sham in saline 
treated rats (U = 0, p = 0.006). However, in DSP-4 treated rats there was no difference in neuronal 
activation between sham and stimulated animals (U = 7, p = 0.144) (Data are expressed as median and 
interquartile ranges, black scale bar = 200 µm, **p = 0.006). 4V = 4th ventricle, DBHir = area 
immunoreactive for DBH, ir = immunoreactive, STIM = electrically stimulated. 
 
Figure 3. Trigeminovascular activation is modulated by LC adrenoceptors. Time course changes in the 
average response of dural-evoked Aδ-fiber trigeminal neurons after microinjections in the locus coeruleus 
(LC). (A) Microinjection of the α2-adrenoceptor agonist clonidine induced a concentration-dependent 
reduction of the dural-evoked neuronal activation in the TCC when compared to the vehicle control group 
(F4.45,66.8 = 12.96, p < 0.0001), reaching a significant decrease at 30 minutes after injection of the lowest 
concentration (1mg/ml, t(12) = -2.72, p = 0.019) and at 5 minutes after injection of the highest 
concentration (10mg/ml, t(9) = -7.56, p < 0.001). Pre-treatment with the α2-adrenoceptor antagonist 
yohimbine blocked the inhibitory effect (F11,77 = 0.88, p = 0.561). (B) Microinjection of the α2-adrenoceptor 
antagonist yohimbine alone had no significant effect on dural-evoked trigeminovascular activation in the 
TCC when compared to the vehicle control group (F11,110 = 0.44, p = 0.94). (C) Microinjection of α1-
adrenoceptor agonist phenylephrine in the LC induced a biphasic response in dural-evoked activation in 
the TCC. This response was characterised by an initial significant reduction of the neuronal activation to 
81 % ± 5 that lasted 15 minutes (at 5 min: t(10) = -2.61, p = 0.026; at 15 min: t(10) = -2.54, p = 0.029), followed 
by a significant increase, reaching its maximum of 118% ± 8 at 60 minutes post injection (t(10) = 3, p = 
0.013). (Data are expressed as mean ± SEM, *p < 0.05). 
 
Figure 4. Chronic disruption of the LC increases susceptibility to cortical spreading depression (CSD). (A) 
The electrical threshold (measured as the current intensity times stimulus duration; microCoulombs (µC)) 
to induce a CSD was significantly lower in the animals with their LC disrupted (U = 43, p = 0.036) indicating 
an increased susceptibility to CSD (Data are expressed as median and interquartile range in a logarithmic 
scale, *p < 0.05). In vivo cortical DC shift readings in a LC-intact (B) and a LC-disrupted (C) representative 
animal showing the application of increasing electric charges until a CSD was achieved. (D) Schematic 
representation of the experimental setup of CSD as a preclinical model of migraine aura. The electrical 
threshold to develop a CSD was determined on the left hemisphere by stimulating with a bipolar electrode 
increasing the electric charge. Once a CSD was induced, the number of KCl-induced CSDs was determined 
on the right hemisphere by placing a cotton ball soaked in 1M KCl. (E) The number of KCl-induced CSDs 
was significantly higher in the animals with their LC disrupted (t(23) = -2.5, p = 0.018) confirming an 
increased susceptibility to CSD (Data are expressed as mean ± SEM). In vivo cortical direct current (DC)-
shift readings in a LC-intact (F) and a LC-disrupted (G) representative animal showing the application of a 
cotton ball soaked in 1M KCl on the cortex surface (which was refreshed with 5µl every 15 minutes, black 
circles) inducing multiple CSDs throughout the 1-hour recording. 
 
Figure 5: The locus coeruleus and migraine. The noradrenergic system plays a crucial role in the 
regulation of arousal and nociception. As one of the major sources of noradrenaline in the central 
nervous system we sought to determine the role of the locus coeruleus (LC) in migraine 
pathophysiology. (A) Trigeminal nociceptive input from the head is conveyed via primary afferents 
arising in the trigeminal ganglion (TG) that synapse centrally on the trigeminocervical complex (TCC). 
From the TCC, ascending projections largely target the sensory thalamic nuclei; however, excitatory 
projections also target the LC resulting in its activation. During wakefulness, the LC receives descending 
excitatory projections from the hypothalamus that promote its activation (green arrow). In turn, the LC 
sends noradrenergic projections to most of the CNS, including descending projections to the TCC and 
spinal cord, as well as ascending projections to the thalamus and cortex, having roles in arousal and 
nociceptive processing. (B) We have demonstrated that loss of LC noradrenergic signalling inhibits 
trigeminal nociceptive signalling at the level of the TCC, while paradoxically increasing the susceptibility 
to cortical spreading depression (CSD). As such, we propose that inhibition of the LC exerts a potent 
anti-nociceptive effect on trigeminal nociceptive processing. As the LC shows diurnal activity, falling 
almost completely silent during, sleep we further hypothesise that sleep-induced LC inhibition may be a 
potential mechanism. 
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